Arrowhead Pharmaceuticals Inc. — Sponsor Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

4 Recruiting

9 Completed trials

20 Countries active

5 Unique IMPs

100% Results reported

Phase III

Phase I/II

Phase III: 7 Phase II: 1 Phase I/II: 3 Phase I: 1 Phase I (FiH): 1

Oversight events:

2 temporary halts across 1 trial

View oversight register →

100%

9 of 9 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Asthma 2 Immune-mediated renal disorder 1 Idiopathic pulmonary fibrosis 1 Chronic obstructive pulmonary disease 1

Top IMPs

SYNTHETIC DOUBLE-STRANDED SIRNA OLIGONUCLEOTIDE DIRECTED AGAINST APOLIPOPROTEIN C-III MRNA AND COVALENTLY LINKED TO A LIGAND CONTAINING THREE N-ACETYLGALACTOSAMINE RESIDUES 7 ADS-011 1 ADS-013 1 ADS-015 1 ZODASIRAN 1

All trials

13 total

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) Recruiting

2025-521792-31-01 Phase III 10 countries ZODASIRAN
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting

2024-519712-13-00 Phase III 14 countries SYNTHETIC DOUBLE-STRANDED SIRNA OLIGONUCLEOTIDE DIRECTED AGAINST APOLIPOPROTEIN …
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 Recruiting

2024-514763-25-01 Phase I 4 countries
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia at high risk of Acute Pancreatitis (SHASTA-5 Study) Recruiting

2024-518206-40-00 Phase III 5 countries SYNTHETIC DOUBLE-STRANDED SIRNA OLIGONUCLEOTIDE DIRECTED AGAINST APOLIPOPROTEIN …
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study) Ended

2023-509301-80-00 Phase III 10 countries SYNTHETIC DOUBLE-STRANDED SIRNA OLIGONUCLEOTIDE DIRECTED AGAINST APOLIPOPROTEIN …
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended

2023-509302-30-00 Phase III 9 countries SYNTHETIC DOUBLE-STRANDED SIRNA OLIGONUCLEOTIDE DIRECTED AGAINST APOLIPOPROTEIN …
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA 3 Study) Ended

2023-509300-14-00 Phase III 10 countries SYNTHETIC DOUBLE-STRANDED SIRNA OLIGONUCLEOTIDE DIRECTED AGAINST APOLIPOPROTEIN …
A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosi… Ended

2023-504964-41-00 Phase I (FiH) 3 countries
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia Ended

2024-511331-96-00 Phase II 3 countries SYNTHETIC DOUBLE-STRANDED SIRNA OLIGONUCLEOTIDE DIRECTED AGAINST APOLIPOPROTEIN …
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-C3 in Adult Healthy V… Ended

2023-506690-36-00 Phase I/II 1 country ADS-011
Study Evaluating the Effects of ARO-RAGE in Healthy Subjects and Patients with Inflammatory Lung Disease Ended

2023-509654-60-00 Phase I/II 2 countries ADS-015
A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients with Muco-Obstructive Lung Dise… Ended

2024-514809-67-00 Phase I/II 2 countries ADS-013
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome Ended

2024-514336-24-00 Phase III 7 countries SYNTHETIC DOUBLE-STRANDED SIRNA OLIGONUCLEOTIDE DIRECTED AGAINST APOLIPOPROTEIN …

Showing 1–13 of 13 trials

← All sponsors A–Z